Johnson & Johnson's CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After...
Johnson & Johnson's CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After...
Johnson & Johnson's CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After Three-year Follow-up In Landmark CARTITUDE-4 Study
CARVYKTI是強生公司首個且唯一的細胞療法，與標準療法相比顯著延長多發性骨髓瘤患者整體生存期，早至於二線；在標誌性CARTITUDE-4研究的三年後隨訪中，CARVYKTI的死亡風險降低45%。
45 percent reduction in risk of death achieved with CARVYKTI after three-year follow-up in landmark CARTITUDE-4 study
CARVYKTI在標誌性CARTITUDE-4研究的三年後隨訪中，死亡風險降低45%。
Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting
數據在2024年國際骨髓瘤學會年會上作爲晚報口頭報告的特色展示。
RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today long-term results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI (ciltacabtagene autoleucel) significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), reducing the risk of death by 45 percent versus standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).1 With these data, CARVYKTI is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as second line.1 Findings were featured as a late-breaking oral presentation at the 2024 International Myeloma Society (IMS) Annual Meeting (Abstract #OA-65).1
2024年9月27日，里約熱內盧 / PRNewswire -- 強生公司（紐交所：JNJ）今日宣佈來自第3期CARTITUDE-4研究的長期結果，顯示單次注射CARVYKTI（西達卡巴標記細胞自體淋巴細胞）在曾接受至少一種前線療法的多發性骨髓瘤患者中顯著延長整體生存期（OS），包括蛋白酶體抑制劑（PI），將死亡風險降低45%與標準療法泊馬利度胺、硼替佐米和地塞米松（PVd）或達美康胺、泊馬利度胺和地塞米松（DPd）相比。有了這些數據，CARVYKTI現在是第一個也是唯一一個細胞療法，可以早至於二線改善OS，與標準療法相比對多發性骨髓瘤患者的萊那利胺耐藥變體。發現在2024年國際骨髓瘤學會（IMS）年會上作爲晚報口頭報告（摘要編號 #OA-65）。
譯文內容由第三人軟體翻譯。